Lakefront Biotherapeutics (GLPGF) Net Cash Flow Growth (3y) (2018 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 36.60% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -35.85% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -96.44% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 60.45% |
| Dec 31, 2025 | 26.33% |
| Mar 31, 2025 | 26.88% |
| Dec 31, 2024 | 26.28% |
| Jun 30, 2024 | -16.09% |
| Mar 31, 2024 | -30.51% |
| Dec 31, 2023 | 10.94% |
| Mar 31, 2023 | -34.47% |
| Dec 31, 2022 | 22.94% |
| Mar 31, 2022 | -138.05% |
| Dec 31, 2021 | -26.03% |
| Jun 30, 2021 | 57.36% |
| Mar 31, 2021 | 128.59% |
| Dec 31, 2020 | -43.13% |
| Jun 30, 2020 | -26.02% |
| Mar 31, 2020 | 277.07% |
| Dec 31, 2019 | -691.14% |
| Jun 30, 2019 | -51.50% |
| Mar 31, 2019 | -28.40% |
| Dec 31, 2018 | 1,260.74% |